60 results
424B3
SLGL
Sol-Gel Technologies Ltd
4 Apr 24
Prospectus supplement
9:05am
to successfully integrate SGT-610 into our product candidate pipeline, and the benefits of and projections of our future financial performance as a result … their participation in our clinical trials;
our ability to complete the development of our product candidates;
our ability to obtain the benefits associated
POS AM
SLGL
Sol-Gel Technologies Ltd
20 Mar 24
Prospectus update (post-effective amendment)
4:05pm
;
ability to successfully integrate SGT-610 into our product candidate pipeline, and the benefits of and projections of our future financial … the benefits associated with orphan drug designation, such as orphan drug exclusivity and, even if we do, that exclusivity may not prevent the U.S. Food and Drug
424B3
8l04ufvi4n0d
10 Aug 23
Prospectus supplement
7:20am
6-K
EX-99.1
mj1nqsmm2omm
10 Aug 23
Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:10am
6-K
EX-99.1
g3i7c 560
21 Jun 23
Notice of Annual Meeting of Shareholders
9:38am
6-K
EX-99.1
tbjbib3
6 Jun 23
Sol-Gel and Searchlight Pharma Announce Licensing Agreements to
7:15am
424B3
xx4lj6
12 May 23
Prospectus supplement
9:15am
6-K
EX-99.1
k38xup vqw
12 May 23
Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides
12:00am
6-K
EX-99.1
ozsdfxdta8rgw gbtjtr
21 Nov 22
Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:42pm
6-K
EX-99.1
fcdp2
3 Oct 22
Sol-Gel Technologies Appoints Michael Glezin Vice
8:05am
6-K
EX-99.1
lklt27of yhs3
4 Aug 22
Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
9:32am
6-K
EX-99.1
zukt5u8y4wat8
8 Jun 22
Current report (foreign)
7:15am
6-K/A
EX-99.1
4obw6z5m6 sp9
23 May 22
Notice of Annual Meeting of Shareholders
4:05pm
6-K
EX-99.1
mgce9c5quhdvi3ys38n
19 May 22
Notice of Annual Meeting of Shareholders
4:30pm
6-K
EX-99.1
ff230
16 May 22
Current report (foreign)
7:35am